AI Prescription Refills Launch in Utah, Sparking Medical Debate

A new program allowing Utah residents to get their prescriptions refilled by an artificial intelligence chatbot — without seeing a doctor — has sparked a fierce national debate over whether AI is ready to take on tasks that have been the exclusive domain of licensed physicians for more than a century.

What the Program Does

Launched quietly in January, the program allows Utah residents to visit a website built by AI healthcare company Doctronic, verify their identity, and interact with an AI chatbot that asks about their prescriptions and medical history. The system checks for a valid prescription through a national pharmacy database and, if no issues are flagged, renews the prescription and sends it directly to a local pharmacy. If a case requires additional review, the chatbot transfers the patient to a human physician working for Doctronic’s telehealth service.

The list of medications eligible for AI refills currently includes approximately 190 drugs, among them blood thinners — a category that doctors have specifically flagged as high-risk for automated renewal. Several medications have been removed since launch, including a drug for irregular heartbeats, following safety concerns.

How It Became Legal

Doctronic was able to launch thanks to a Utah “regulatory sandbox” that allows state officials to waive existing laws for AI companies offering promising technology. The arrangement means that laws limiting prescribing authority to licensed medical professionals — the legal foundation of American medicine for over 100 years — do not currently apply to Doctronic’s operations in the state.

Dr. Adam Oskowitz, co-founder of Doctronic, described the company’s goal as meeting patients where they need healthcare. He envisions expanding the model so that AI can one day handle many routine medical tasks, including ordering and interpreting tests, allowing individual physicians to manage far more patients than currently possible.

During the program’s initial phase, human doctors review all AI-generated refill orders. The company expects to transition to fully automated refills in the near future.

Medical Community Raises Alarms

The Utah State Medical Board learned of the program’s launch through news reports. In March, 11 board members signed a letter calling for the program to be halted, citing risks associated with automatically renewing medications that can cause dangerous side effects or interact with other drugs. The board was told the program would continue regardless.

“We were essentially told: ‘Yes this is going on. And no, you don’t have a say in it,'” said Dr. Alan Smith, a family physician who chairs the board. Smith said the risks are not theoretical — patients’ medical circumstances can change significantly between prescription refills. “Many times when I see people after six months I find that their medical history or situation has changed. Just because something was prescribed before does not mean it’s appropriate now.”

The American Medical Association has voiced similar concerns, warning that “prescription renewals aren’t routine checkboxes.” Dr. Eric Bressman of the University of Pennsylvania said the medical community is not categorically opposed to AI prescribing, but believes it must meet the same rigorous standards applied to human physicians — years of training, testing, and independent licensing. “We have crossed a threshold in terms of giving something that is not human a medical license, whether or not we want to call it that,” Bressman said.

Regulatory Gray Zone: State vs. Federal Authority

The AI prescription refills Utah Doctronic program sits in an ambiguous regulatory space. Medical technology is traditionally overseen at the federal level by the FDA, while medical professionals are licensed at the state level. Doctronic’s executives consider their AI part of the state-regulated practice of medicine — but experts argue the system may cross a line that brings it under FDA jurisdiction.

When asked whether the company had sought FDA authorization, Doctronic’s executives declined to say. “We try not to get too deep into the weeds on the regulatory side,” Oskowitz said. An FDA spokesperson said the agency has not authorized any AI chatbots but is “committed to encouraging medical innovation” while keeping safety central — a statement interpreted by critics as a hands-off posture under the current administration.

Accuracy Data and Transparency Concerns

Utah has released some initial program data, and Doctronic has said it plans to publish peer-reviewed studies later this year. As of now, the only published research on its technology is a company-authored paper that has not undergone independent review. That study found Doctronic matched human physician diagnoses 80% of the time across 500 telehealth consultations.

Bressman said Utah should have required robust data before allowing the program to launch rather than accepting the company’s assurances on good faith. “Mostly they’re accepting the company’s word on good faith that they’re up to the task,” he said, comparing the current moment to the chaotic medical standards of the early 20th century before national licensing benchmarks were established.

Spreading to Other States

Utah is not alone. Texas and Wyoming are also waiving regulations for AI healthcare companies. Iowa, Idaho, and several other states have introduced legislation to formally license AI medical services, many modeled on a template from the Cicero Institute, a pro-AI think tank co-founded by Palantir co-founder Joe Lonsdale.

Adam Meier, Cicero’s director for health policy, attributed much of the opposition to economic self-interest among physicians. “Whoever goes first is going to take the slings and arrows because there’s economic interests, concerns about the workforce and what that’s going to mean for jobs,” he said.

Daniel Aaron, a law professor at the University of Utah, offered a more cautious long-term view. “Companies may benefit in the short term by expanding their business models and kind of having the technology go beyond the evidence. But in the long-term, I think they risk compromising public trust and fueling backlash.”